



**Recommendation to the Cancer Systemic Therapy Policy Committee (CSTPC)
from Capital District Health Authority/*Cancer Care Nova Scotia***

**Guidelines for the Role of Sorafenib in Advanced or Metastatic Renal Cell
Carcinoma (RCC)**

Approved Use:

Sorafenib: As a **single agent second line treatment** in patients with documented evidence of histologically confirmed advanced or metastatic clear cell RCC, considered to be intermediate or low risk (according to Memorial Sloan-Kettering (MSKCC) prognostic score), have an ECOG performance status of 0 or 1 and progressed after prior cytokine therapy (or intolerance) within the previous 8 months. In any one patient, all of the following conditions must be met:

1. Sorafenib may be a second line option only after cytokine therapy.
 2. Sorafenib may not be used after another tyrosine kinase inhibitor (i.e. sunitinib) as sequential therapy.
 3. In the event of severe toxicity within the first 8 weeks of therapy, a switch to another tyrosine kinase inhibitor (i.e. sunitinib) may be allowed.
- This policy recommendation represents a **new guideline document** and a restriction of sorafenib to include advanced or metastatic RCC patients as a second line therapy option.